Abbott Laboratories (ABT) is back in focus after beating quarterly estimates and raising its annual profit forecast, pointing investors toward the company’s cancer diagnostics and medical devices businesses as key earnings drivers.

The recent earnings beat and guidance raise come alongside a strong 90 day share price return of 28.77% and a 30 day share price return of 15.64%, although the year to date share price return is still down 12.54% and the 1 year total shareholder return is down 15.40%. This suggests momentum has picked up recently even as longer term holders remain under water.

If Abbott Laboratories’s update has you thinking more broadly about healthcare opportunities, it could be worth scanning for other specialised healthcare AI plays through the Simply Wall St screener for 43 healthcare AI stocks

Abbott Laboratories’ sharp rebound sits at the crossroads of two stories. One points to firmer earnings from diagnostics and devices; the other to a quick shift in sentiment. How does the current valuation stack up against those signals?

Most Popular Narrative: 8.8% Undervalued

With Abbott Laboratories last closing at $108.62 against a narrative fair value of $119.13, the current setup hinges on how earnings and margins evolve from here.

The global demographic shift toward an aging population and increasing prevalence of chronic and lifestyle-related diseases (e.g., diabetes, cardiovascular disease) is underpinning strong, recurring demand for Abbott's diagnostics, nutrition (e.g., Ensure, Glucerna), and high-growth medical device franchises, which in turn is supporting revenue acceleration and enhanced operating leverage.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that fair value for Abbott Laboratories? The narrative leans on faster top line growth, rising margins and a richer earnings multiple. Curious which specific growth and profitability assumptions make the numbers work.

Result: Fair Value of $119.13 (UNDERVALUED)

However, investors still need to watch diagnostic pricing pressure in China and foreign exchange swings, which could weigh on Abbott Laboratories’ margins and earnings power.

Next Steps

With mixed sentiment around Abbott Laboratories, and both risks and rewards in play, it makes sense to review the numbers yourself and move promptly. To see how the upside and downside compare in one place, take a closer look at the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Abbott Laboratories?

If Abbott Laboratories has sharpened your interest in new opportunities, do not stop here. Let the Simply Wall St screener point you toward other focused ideas.

• Target reliable income potential by reviewing companies in the 9 dividend fortresses that may suit a more cash focused approach.
• Hunt for mispriced opportunities by checking the 51 high quality undervalued stocks and see which stocks align with your return expectations.
• Prioritise resilience by scanning the 83 resilient stocks with low risk scores so you do not miss stocks with steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.